Recent advances in synthetic analogues of lantibiotics: What can we learn from these?
The lantibiotics are a family of antibacterial cyclic peptides distinguished by one or more thioether linkages between amino acid side chains, and by unique modes of action. Recent developments in the chemical synthesis, mutagenesis and mutasynthesis of these peptides are providing insights into the...
Gespeichert in:
| Veröffentlicht in: | Bioorganic chemistry 2014-08, Vol.55, p.39-50 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 50 |
|---|---|
| container_issue | |
| container_start_page | 39 |
| container_title | Bioorganic chemistry |
| container_volume | 55 |
| creator | Tabor, Alethea B. |
| description | The lantibiotics are a family of antibacterial cyclic peptides distinguished by one or more thioether linkages between amino acid side chains, and by unique modes of action. Recent developments in the chemical synthesis, mutagenesis and mutasynthesis of these peptides are providing insights into the structural requirements for antibacterial activity and into the mode of action, as well as having the potential to produce analogues with greater stability, potency and bioavailability. This Review provides a survey of these recent advances. |
| doi_str_mv | 10.1016/j.bioorg.2014.04.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1552809274</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0045206814000285</els_id><sourcerecordid>1552809274</sourcerecordid><originalsourceid>FETCH-LOGICAL-c432t-24f5f1b779e6e7598cdb17320bbecc877216a0c802e55f201ed7a7d4b541d1b13</originalsourceid><addsrcrecordid>eNp9UE1LAzEQDaLYWv0HIjl62TqTZjdbD4oUv0AQRPEYstlZTdluarKt-O9NqXoUBgZm3pv35jF2jDBGwOJsPq6c9-FtLADlGFKB3GFDhClkAgXssmGa5JmAohywgxjnAIhSFftsIGSpVIGTIXt5Iktdz029Np2lyF3H41fXv1PvLDedaf3bKo19w1vT9S5ppkU856_vpufWdPyTeEsmdLwJfsETMdLlIdtrTBvp6KeP2MvN9fPsLnt4vL2fXT1kVk5EnwnZ5A1WSk2pIJVPS1tXqCYCqoqsTRYFFgZsCYLyvEl_Uq2MqmWVS6yxwsmInW7vLoP_SDZ7vXDRUpuskl9FjXkuSpgKJRNUbqE2-BgDNXoZ3MKEL42gN4Hqud4GqjeBakgFG9rJj8KqWlD9R_pNMAEutgBKf64dBR2toxRl7QLZXtfe_a_wDa3ziIo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1552809274</pqid></control><display><type>article</type><title>Recent advances in synthetic analogues of lantibiotics: What can we learn from these?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Tabor, Alethea B.</creator><creatorcontrib>Tabor, Alethea B.</creatorcontrib><description>The lantibiotics are a family of antibacterial cyclic peptides distinguished by one or more thioether linkages between amino acid side chains, and by unique modes of action. Recent developments in the chemical synthesis, mutagenesis and mutasynthesis of these peptides are providing insights into the structural requirements for antibacterial activity and into the mode of action, as well as having the potential to produce analogues with greater stability, potency and bioavailability. This Review provides a survey of these recent advances.</description><identifier>ISSN: 0045-2068</identifier><identifier>EISSN: 1090-2120</identifier><identifier>DOI: 10.1016/j.bioorg.2014.04.004</identifier><identifier>PMID: 24877613</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Anti-Bacterial Agents - pharmacology ; Antibacterial ; Bacteria - drug effects ; Bacterial Infections - drug therapy ; Bacteriocins - chemistry ; Bacteriocins - pharmacology ; Humans ; Lantibiotic ; Peptide ; Peptides, Cyclic - chemistry ; Peptides, Cyclic - pharmacology</subject><ispartof>Bioorganic chemistry, 2014-08, Vol.55, p.39-50</ispartof><rights>2014 Elsevier Inc.</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c432t-24f5f1b779e6e7598cdb17320bbecc877216a0c802e55f201ed7a7d4b541d1b13</citedby><cites>FETCH-LOGICAL-c432t-24f5f1b779e6e7598cdb17320bbecc877216a0c802e55f201ed7a7d4b541d1b13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0045206814000285$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24877613$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tabor, Alethea B.</creatorcontrib><title>Recent advances in synthetic analogues of lantibiotics: What can we learn from these?</title><title>Bioorganic chemistry</title><addtitle>Bioorg Chem</addtitle><description>The lantibiotics are a family of antibacterial cyclic peptides distinguished by one or more thioether linkages between amino acid side chains, and by unique modes of action. Recent developments in the chemical synthesis, mutagenesis and mutasynthesis of these peptides are providing insights into the structural requirements for antibacterial activity and into the mode of action, as well as having the potential to produce analogues with greater stability, potency and bioavailability. This Review provides a survey of these recent advances.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibacterial</subject><subject>Bacteria - drug effects</subject><subject>Bacterial Infections - drug therapy</subject><subject>Bacteriocins - chemistry</subject><subject>Bacteriocins - pharmacology</subject><subject>Humans</subject><subject>Lantibiotic</subject><subject>Peptide</subject><subject>Peptides, Cyclic - chemistry</subject><subject>Peptides, Cyclic - pharmacology</subject><issn>0045-2068</issn><issn>1090-2120</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UE1LAzEQDaLYWv0HIjl62TqTZjdbD4oUv0AQRPEYstlZTdluarKt-O9NqXoUBgZm3pv35jF2jDBGwOJsPq6c9-FtLADlGFKB3GFDhClkAgXssmGa5JmAohywgxjnAIhSFftsIGSpVIGTIXt5Iktdz029Np2lyF3H41fXv1PvLDedaf3bKo19w1vT9S5ppkU856_vpufWdPyTeEsmdLwJfsETMdLlIdtrTBvp6KeP2MvN9fPsLnt4vL2fXT1kVk5EnwnZ5A1WSk2pIJVPS1tXqCYCqoqsTRYFFgZsCYLyvEl_Uq2MqmWVS6yxwsmInW7vLoP_SDZ7vXDRUpuskl9FjXkuSpgKJRNUbqE2-BgDNXoZ3MKEL42gN4Hqud4GqjeBakgFG9rJj8KqWlD9R_pNMAEutgBKf64dBR2toxRl7QLZXtfe_a_wDa3ziIo</recordid><startdate>20140801</startdate><enddate>20140801</enddate><creator>Tabor, Alethea B.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140801</creationdate><title>Recent advances in synthetic analogues of lantibiotics: What can we learn from these?</title><author>Tabor, Alethea B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c432t-24f5f1b779e6e7598cdb17320bbecc877216a0c802e55f201ed7a7d4b541d1b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibacterial</topic><topic>Bacteria - drug effects</topic><topic>Bacterial Infections - drug therapy</topic><topic>Bacteriocins - chemistry</topic><topic>Bacteriocins - pharmacology</topic><topic>Humans</topic><topic>Lantibiotic</topic><topic>Peptide</topic><topic>Peptides, Cyclic - chemistry</topic><topic>Peptides, Cyclic - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tabor, Alethea B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tabor, Alethea B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent advances in synthetic analogues of lantibiotics: What can we learn from these?</atitle><jtitle>Bioorganic chemistry</jtitle><addtitle>Bioorg Chem</addtitle><date>2014-08-01</date><risdate>2014</risdate><volume>55</volume><spage>39</spage><epage>50</epage><pages>39-50</pages><issn>0045-2068</issn><eissn>1090-2120</eissn><abstract>The lantibiotics are a family of antibacterial cyclic peptides distinguished by one or more thioether linkages between amino acid side chains, and by unique modes of action. Recent developments in the chemical synthesis, mutagenesis and mutasynthesis of these peptides are providing insights into the structural requirements for antibacterial activity and into the mode of action, as well as having the potential to produce analogues with greater stability, potency and bioavailability. This Review provides a survey of these recent advances.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24877613</pmid><doi>10.1016/j.bioorg.2014.04.004</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0045-2068 |
| ispartof | Bioorganic chemistry, 2014-08, Vol.55, p.39-50 |
| issn | 0045-2068 1090-2120 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1552809274 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Animals Anti-Bacterial Agents - pharmacology Antibacterial Bacteria - drug effects Bacterial Infections - drug therapy Bacteriocins - chemistry Bacteriocins - pharmacology Humans Lantibiotic Peptide Peptides, Cyclic - chemistry Peptides, Cyclic - pharmacology |
| title | Recent advances in synthetic analogues of lantibiotics: What can we learn from these? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A50%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20advances%20in%20synthetic%20analogues%20of%20lantibiotics:%20What%20can%20we%20learn%20from%20these?&rft.jtitle=Bioorganic%20chemistry&rft.au=Tabor,%20Alethea%20B.&rft.date=2014-08-01&rft.volume=55&rft.spage=39&rft.epage=50&rft.pages=39-50&rft.issn=0045-2068&rft.eissn=1090-2120&rft_id=info:doi/10.1016/j.bioorg.2014.04.004&rft_dat=%3Cproquest_cross%3E1552809274%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1552809274&rft_id=info:pmid/24877613&rft_els_id=S0045206814000285&rfr_iscdi=true |